<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): JULY 8, 1996
------------
MATRITECH, INC.
---------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
---------------------------------------------------------------
(State or other jurisdiction of incorporation)
1-12128 4-2985132
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
330 NEVADA STREET, NEWTON, MASSACHUSETTS 02160 USA
----------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(617) 928-0820
--------------
Page 1 of 3 Pages
<PAGE>
ITEM 5. OTHER EVENTS.
------------
U.S. FOOD AND DRUG ADMINISTRATION APPROVAL
------------------------------------------
Matritech, Inc. (the "Company") announced on July 8, 1996 that its
Matritech NMP22/TM Test Kit has been approved by the U.S. Food and Drug
Administration (the "FDA") for sale in the United States for use in identifying
patients at risk for recurrence of bladder cancer.
Page 2 of 3 Pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Current Report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized, in the City of Newton,
Commonwealth of Massachusetts, on this 9th day of July, 1996.
MATRITECH, INC.
By: /s/ Stephen D. Chubb
--------------------
Name: Stephen D. Chubb
Title: Chairman, Director and
Chief Executive Officer
Page 3 of 3 Pages
